Hepatitis C virus (HCV) coinfection in individuals living with human immunodeficiency virus (HIV) (PLWH) may affect lipid metabolism and accelerate the progression of chronic hepatitis. Therefore, the identification of risk factors for progressive liver disease is needed. The present study aimed to examine the prevalence and clinical features associated with liver fibrosis in HCV‑coinfected HIV patients, including metabolic markers. A total of 105 patients coinfected with HIV and HCV were recruited and liver fibrosis was assessed using the fibrosis‑4 (FIB‑4) score and aspartate aminotransferase‑to‑platelet ratio index (APRI). Logistic regression analyses indicated that patients aged >50 years and with a CD4⁺ cell count <350 cells/µl had an 11.4‑times higher (P=0.001) and a 5.7‑times higher (P=0.017) risk of liver fibrosis, as determined by FIB‑4 score, compared to patients aged ≤40 years and a CD4⁺ cell count of ≥350 cells/µl, respectively. In addition, patients naïve to HCV treatment or receiving treatment had 5.4‑ and 12.7‑times higher risks for liver fibrosis, as determined by APRI, than those with sustained virologic response (SVR) (P=0.003 and P=0.033, respectively). Univariate analysis indicated lower risks of liver fibrosis, as determined by APRI, in the patients with abnormally high levels of cholesterol, high‑density lipoprotein (HDL) and low‑density lipoprotein (LDL) than those with normal levels [odds ratio (OR) 0.3, 95% confidence interval (CI) 0.1‑0.9, P=0.037; OR 0.4, 95% CI 0.2‑0.9, P=0.041; OR 0.2, 95% CI 0.1‑0.5, P=0.001] and multivariate analysis suggested only patients with high levels of LDL had a lower risk for liver fibrosis determined by APRI (OR 0.1, 95% CI 0.3‑0.8, P=0.029). Consistently, serum levels of cholesterol, HDL and LDL were significantly lower in the patient groups with more advanced fibrosis, evaluated by FIB‑4 score and APRI, than those without liver fibrosis and the levels of cholesterol and LDL in the patients achieving SVR were higher than those with no response or not receiving treatment (all P<0.05). In conclusion, the present study identified serum lipid levels as associated factors of hepatic fibrosis, together with age, CD4⁺ cell count and HCV treatment status, in HCV‑coinfected PLWH on long‑term suppressive anti‑retroviral therapy.

Related Articles